The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
YORVIPATH (Specialised Therapeutics Pharma Pty Ltd)
Product name
YORVIPATH
Date registered
Evaluation commenced
Decision date
Approval time
150 (255 working days)
Active ingredients
palopegteriparatide
Registration type
NCE/ NBE
Indication
Yorvipath (palopegteriparatide) is a parathyroid hormone (PTH) analogue indicated for the treatment of chronic hypoparathyroidism in adults.